Mydecine Innovations Group Inc.
MYCO
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -68.29% | -56.49% | -58.69% | -70.47% | -68.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -121.39% | -96.02% | -64.21% | -73.23% | -46.88% |
| Operating Income | 121.39% | 96.02% | 64.21% | 73.23% | 46.88% |
| Income Before Tax | 117.91% | 101.46% | 78.63% | 84.75% | 33.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 117.91% | 101.46% | 78.63% | 84.75% | 33.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 117.91% | 101.46% | 78.63% | 84.75% | -3.31% |
| EBIT | 121.39% | 96.02% | 64.21% | 73.23% | 46.88% |
| EBITDA | 128.36% | 105.58% | 69.88% | 73.31% | 46.87% |
| EPS Basic | 115.62% | 101.18% | 86.53% | 93.53% | 56.58% |
| Normalized Basic EPS | 106.77% | 92.71% | 80.32% | 85.93% | 71.08% |
| EPS Diluted | 115.62% | 101.18% | 86.53% | 93.53% | 56.58% |
| Normalized Diluted EPS | 106.77% | 92.71% | 80.32% | 85.93% | 71.08% |
| Average Basic Shares Outstanding | 9.14% | 27.79% | 56.73% | 95.51% | 165.88% |
| Average Diluted Shares Outstanding | 9.14% | 27.79% | 56.73% | 95.51% | 165.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |